This HTML5 document contains 86 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q71775721
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu n'ochobre de 1995 scientific article published on 01 October 1995 wetenschappelijk artikel наукова стаття, опублікована в жовтні 1995 im Oktober 1995 veröffentlichter wissenschaftlicher Artikel
p:P577
wds:Q71775721-CF296F16-431F-4F1A-A569-AD973582F558
wdt:P577
1995-10-01T00:00:00Z
p:P407
wds:Q71775721-589C523E-00EA-4E2F-AE37-3F9D18E11C79
wdt:P407
wd:Q1860
p:P2860
wds:Q71775721-AC62C3CD-504D-41D6-87FC-E9CD84592617 wds:Q71775721-AFA348C6-2344-45DA-B3ED-C34B906E2FA6 wds:Q71775721-08370036-1943-4D3B-9897-4CBF62B8626E wds:Q71775721-1C4ADF7C-B002-463E-BB62-97B4F35BF385 wds:Q71775721-1E2EAA5A-3A5B-4298-9D68-D0AB86E88C4B wds:Q71775721-3351C192-A52E-4B74-9BE3-0274A44C2241 wds:Q71775721-4C5B3155-3501-4126-A911-CE5BCA2EFB68 wds:Q71775721-52F47D5C-D8FA-4264-B512-38C12EA0940D wds:Q71775721-21E65CC7-5014-4C9B-B112-736E81ADEDCC wds:Q71775721-24BE132A-587B-426D-B25D-4E7495484576 wds:Q71775721-2E2DFCB6-4502-4905-A5CA-3EC88EDBAF3C wds:Q71775721-E1E462F8-6F0D-4943-BF61-428D5DC19F4B wds:Q71775721-F11275AA-E176-4CED-9131-58A10A64E25C wds:Q71775721-DBBA2702-97AD-42B8-9B03-B100B86EB24C wds:Q71775721-7FF5F7D1-D644-438D-A6AD-3E5F03502B93 wds:Q71775721-8689BB3C-D64D-40FD-B3FE-4DCC8328A7BD wds:Q71775721-92453797-190B-4968-A30E-544E79A505C8 wds:Q71775721-54443738-256E-4008-90D9-D8A4734232D5 wds:Q71775721-BA0E8EB7-B33A-40E5-9331-6FE195F27936 wds:Q71775721-C986A873-2644-4E52-B30B-41E927D321FA
wdt:P2860
wd:Q44191102 wd:Q71177671 wd:Q33642036 wd:Q72218886 wd:Q41199397 wd:Q36451647 wd:Q68325970 wd:Q28327406 wd:Q68186892 wd:Q72924068 wd:Q69534009 wd:Q40281710 wd:Q70194937 wd:Q28331250 wd:Q36446879 wd:Q36428069 wd:Q36499431 wd:Q36415395 wd:Q71814824 wd:Q70237689
p:P2093
wds:Q71775721-17ECE890-01DB-43AF-8FED-21BA3E37E172 wds:Q71775721-9355AB2E-C270-4EF9-9354-E5A649C0BBCF wds:Q71775721-A0C86419-D43F-4CC3-9CD3-C52A6DA88C91 wds:Q71775721-BB7B08A9-8285-4EED-8650-5EC42CB0AC77 wds:Q71775721-BA57BB15-5079-4182-980C-CC622EB4AC57 wds:Q71775721-F2E0DAC3-5BCD-448C-8BBE-70F9AE26E263
wdt:P2093
R Ritch B Smythe A L Robin R P Lehmann T Mundorf D H Shin
rdfs:label
Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group
skos:prefLabel
Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group
schema:name
Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group
p:P1476
wds:Q71775721-2DE386C7-1E49-43D9-A72A-79BE28ABEC66
wdt:P1476
Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group
p:P304
wds:Q71775721-9277601C-8C4B-42DD-9F28-679F4AD27CEF
wdt:P304
423-432
p:P31
wds:Q71775721-33229CF1-33BB-4636-A181-5363854569A3
wdt:P31
wd:Q13442814
p:P698
wds:Q71775721-D4237544-5EA7-404C-830A-E393144752A4
wdtn:P698
n9:7573299
wdt:P698
7573299
p:P1433
wds:Q71775721-7C6855DF-BFBC-4A4F-8434-1D854512E878
wdt:P1433
wd:Q4744258
p:P433
wds:Q71775721-CE097A93-9F4B-41D1-BDEF-DA4C4363ADF7
p:P478
wds:Q71775721-FE2E467C-EC0C-4CD6-954C-8BF041080A61
wdt:P433
4
wdt:P478
120
p:P356
wds:Q71775721-544E596E-F024-4DDA-A326-F7EFEA0DEB6A
wdtn:P356
n11:S0002-9394(14)72655-8
wdt:P356
10.1016/S0002-9394(14)72655-8